1. Home
  2. RFL vs QNCX Comparison

RFL vs QNCX Comparison

Compare RFL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RFL
  • QNCX
  • Stock Information
  • Founded
  • RFL 2017
  • QNCX 2012
  • Country
  • RFL United States
  • QNCX United States
  • Employees
  • RFL N/A
  • QNCX N/A
  • Industry
  • RFL Real Estate
  • QNCX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RFL Finance
  • QNCX Health Care
  • Exchange
  • RFL Nasdaq
  • QNCX Nasdaq
  • Market Cap
  • RFL 48.4M
  • QNCX 47.7M
  • IPO Year
  • RFL N/A
  • QNCX 2019
  • Fundamental
  • Price
  • RFL $1.66
  • QNCX $1.50
  • Analyst Decision
  • RFL
  • QNCX Strong Buy
  • Analyst Count
  • RFL 0
  • QNCX 5
  • Target Price
  • RFL N/A
  • QNCX $8.00
  • AVG Volume (30 Days)
  • RFL 450.8K
  • QNCX 305.4K
  • Earning Date
  • RFL 06-11-2025
  • QNCX 08-12-2025
  • Dividend Yield
  • RFL N/A
  • QNCX N/A
  • EPS Growth
  • RFL N/A
  • QNCX N/A
  • EPS
  • RFL N/A
  • QNCX N/A
  • Revenue
  • RFL $732,000.00
  • QNCX N/A
  • Revenue This Year
  • RFL N/A
  • QNCX N/A
  • Revenue Next Year
  • RFL N/A
  • QNCX N/A
  • P/E Ratio
  • RFL N/A
  • QNCX N/A
  • Revenue Growth
  • RFL 35.56
  • QNCX N/A
  • 52 Week Low
  • RFL $1.27
  • QNCX $0.51
  • 52 Week High
  • RFL $3.19
  • QNCX $2.45
  • Technical
  • Relative Strength Index (RSI)
  • RFL 46.95
  • QNCX 65.33
  • Support Level
  • RFL $1.41
  • QNCX $1.29
  • Resistance Level
  • RFL $1.70
  • QNCX $1.62
  • Average True Range (ATR)
  • RFL 0.28
  • QNCX 0.11
  • MACD
  • RFL -0.05
  • QNCX 0.03
  • Stochastic Oscillator
  • RFL 11.63
  • QNCX 74.47

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

Share on Social Networks: